Topical Finasteride Before and After: The Complete Guide

Commissions we earn from partner links on this page do not affect our opinions or evaluations.

Topical finasteride has emerged as a highly discussed alternative to oral therapy for androgenic alopecia (AGA). Its growing popularity stems from an appealing hope: local dihydrotestosterone (DHT) suppression directly at the scalp while reducing systemic exposure and associated side effects seen with oral formulations. This targeted approach aligns with the broader trend toward personalized safety-conscious hair loss treatments, especially among individuals sensitive to hormonal drugs or hesitant about long-term oral use.

Because of this increased interest, countless “before-and-after” photos circulate online, often portraying dramatic transformations that capture public attention. However, many of these images reflect exceptional responders rather than the average outcome, creating an unrealistic sense of what most people can expect.

We’ll take a closer look at this one later.

This article aims to place topical finasteride in context, bringing anecdote and evidence together. We will take a look at real-world patient results and published case studies, compare user-reported experiences with peer-reviewed clinical data, and define what constitutes a realistic regrowth timeline. 

Order topical finasteride today from our #1 recommended hair loss telemedicine service — Ulo

What is Topical Finasteride?

Topical finasteride is a locally applied formulation of the well-known 5ɑ-reductase type II inhibitor, finasteride, specifically developed to target AGA at its source, the scalp. Its primary purpose is to reduce DHT levels within the scalp, directly addressing the hormonal driver of follicle miniaturization and progressive hair thinning.

Mechanism of Action

Finasteride works by blocking the conversion of testosterone to DHT through inhibiting the type II 5ɑ-reductase enzyme, which is particularly concentrated in the outer root sheath of hair follicles¹. Unlike oral finasteride, which leads to widespread systemic DHT reduction (~70%), topical finasteride produces a more localized effect, resulting in lower systemic DHT suppression, typically in the range of 24-48%². 

Formulations and Dosing

Topical finasteride is most often compounded in strengths ranging from 0.005% to 0.25%, with occasional higher-strength formulations (up to 2.5%) available through specialty pharmacies and research channels. The standard regimen involves applying 1 mL of solution, foam, or spray either once or twice daily, directly to the areas of thinning or active hair loss. 

It should be noted that there are currently no FDA-approved topical finasteride products; all formulations are sourced from compounding pharmacies or custom manufacturers. Furthermore, despite its targeted application, complete elimination of systemic absorption cannot be guaranteed.

The Evidence

Across controlled clinical studies, topical finasteride has consistently demonstrated significant efficacy for AGA, with improved hair density, reduced shedding, and generally minimal side effects when compared to placebo or oral finasteride.

Piraccini et al., 2022 (n=458, men)

This phase III, double-blind, randomized controlled trial compared topical 0.25% finasteride, oral finasteride 1 mg, and placebo in men with AGA over 24 weeks³. Both topical and oral treatments resulted in comparable increases in hair count (topical: +20.2; oral: +20.1; placebo:  +6.7%). Topical finasteride led to a serum decline of 34.5%, notably less than the 55.6% reduction with oral therapy. Patient self-assessment scores were similar for both active groups. Adverse events were mild, with only 2.8% of topical users reporting transient sexual symptoms.

Suchonwanit et al., 2019 (n=30, women)

This trial in women evaluated 0.25% finasteride plus 3% minoxidil against minoxidil alone⁴. Both groups saw increased hair counts, but the finasteride combination resulted in significant thickening of the hair shaft (p=0.02) and a 33% serum DHT reduction, compared with an 11% increase in controls. Side effects were limited to mild scalp irritations, with the combination therapy outperforming minoxidil monotherapy.

Suchonwanit et al., 2018 (n=40, men)

A similar design compared 0.25% finasteride and 3% minoxidil versus minoxidil alone in men⁵. Hair density increased more in the combination group (62 hairs/cm2 vs 35, p=0.05), and 63% experienced marked improvement. Systemic DHT suppression was minimal (5-7%), suggesting a favorable safety profile and robust synergy with minoxidil.

Tanglertsampan, 2012 (n=40, men)

In this study, 0.1% finasteride with 3% minoxidil improved global photographic hair assessments over minoxidil alone, despite similar hair count changes⁶. Cosmetic benefit was apparent, but mild dermatitis occurred in a subset of participants.

Hajheydari et al., 2009 (n=38, men)

Comparing topical 1% finasteride gel to oral 1 mg tablets, this study found similar efficacy in terminal hair count and vellus hair ratio⁷. Topical users mainly noted mild erythema, while oral finasteride users reported decreased libido, reinforcing the lower systemic side effect risk of topical approaches.

Mazzarella et al., 1997 (n=52, men and women)

A 64-week trial of 0.005% topical finasteride versus placebo demonstrated a 30% reduction in hair shedding and superior global assessment scores, with no systemic adverse effects reported⁸.

Across these six studies, topical finasteride has shown efficacy, in some cases comparable to oral finasteride, but with much lower rates of systemic side effects or serum DHT reductions. Most adverse effects were mild scalp irritation, with sexual symptoms reported in only 2-3% of cases. 

Why Expectation Setting Matters

Setting realistic expectations is crucial for topical finasteride users, especially given that online “before and after” images tend to showcase the most dramatic responses, often highlighting best-case scenarios that are not representative of the average experience. This trend can mislead people into anticipating a reversal of long-standing baldness, and when results are slower or subtler, disappointment may cause them to abandon the treatment prematurely.

Overestimated expectations can lead to discouragement and poor treatment adherence, while underestimated expectations may cause users to miss out on real, if modest, gains in hair quality and retention. 

Establishing evidence-based benchmarks, such as those from controlled trials, keeps users motivated through the initial “plateau” phase, where visible changes are minimal but treatment efficacy is accruing beneath the surface.

What’s Possible vs What’s Probable

The outcomes of topical finasteride treatment are best viewed as a spectrum ranging from possible to probable responses, with most users falling somewhere in between. At one end, exceptional “hyper-responders” can experience near-complete restoration of hair density, but these cases are rare and should not set expectations for the majority. For most, the probable outcome is mild-to-moderate thickening of existing hair and stabilization of further loss, reflecting the predictable effects seen in clinical trials and real-world practice. 

There are a number of key factors that influence response to treatment, including consistency, concurrent use of minoxidil or microneedling, and genetic sensitivity. Variations in the androgen receptor gene can influence DHT responsiveness and predict who will benefit most from therapy^9,10. Understanding these factors supports more personalized and realistic goal-setting, ensuring users recognize the true therapeutic potential and limitations of topical finasteride.

With all of this in mind, let’s take a look at ten topical finasteride before and after photos.

Anecdotal Case Studies

The accounts shared below are purely informal and have not been independently verified. They solely reflect the personal experiences of each contributor and should not be interpreted as dependable clinical evidence or as medical recommendations.

Case #1: Male (39), 2.5 Years on Topical Finasteride 0.3% + Minoxidil 6%

This 39-year-old male used a combined topical finasteride 0.3% + minoxidil 6% spray, 4–6 sprays nightly, once daily. He complemented the therapy with weekly microneedling/dermastamping (1.5 mm) at the hairline. He observed early filling in of thinning areas by the 2-month mark, progressive thickening across the crown and mid-scalp by month 12, and stable maintenance with cosmetically robust coverage thereafter through the 30-month mark. Overall, he achieved a visual reversal from diffuse thinning to dense coverage at the crown and noticeable thickening at the hairline area. He reported no side effects other than brief brain fog in the first month, which resolved. 

Case #2: 9 Weeks on Topical Finasteride 0.01–0.02% + Topical Minoxidil 5% (Nightly) 

This user used a topical formulation of finasteride prepared by dissolving tablets in a minoxidil solution and straining through a fine-mesh strainer. The solution applied in month 1 was finasteride 0.01%/minoxidil 5%, applied daily to the affected scalp, with the finasteride increased to 0.02% in month 2. He noted a brief 2-3 day shedding phase around week 4, with early visible improvement at the hairline by 9 weeks. He perceived ongoing frontal advancement, while crown stability was not yet observed. The user reported that the topical regimen was well tolerated, with no side effects. 

Case #3: 43-Year-Old Male on Topical Finasteride 0.025% + Minoxidil 5% with Biweekly 0.75 mm Microneedling

This Redditor’s intervention consisted of the solution FINASOL-M (topical finasteride 0.025% in TrichoSol) and topical minoxidil 5%, with 1 ml applied once daily to affected areas using a roll-on applicator. He additionally underwent 0.75 mm dermastamp every 2 weeks, on which days he skipped the topicals. He engaged in regular exercise, followed a balanced diet, and took supplements with magnesium, zinc, vitamin B complex, vitamin D3+K2, and lecithin. 

After 3 months on the regimen, the user noted visible thickening and coverage gains across the vertex. He reported that his topical regimen was well-tolerated with no perceived systemic or sexual side effects. 

Case #4: 23-Year-Old Male on Topical Finasteride + Minoxidil

This 23-year-old male’s therapy included topical finasteride and minoxidil combination spray. However, the concentrations used weren’t mentioned. He applied up to 4 sprays nightly for 3.5 months, in addition to intermittent microneedling. He described a shedding period in the first two months, with minimal visible changes reported. By month 3.5, however, he documented a significant cosmetic improvement with regrowth at the hairline and temples. He reported no systemic side effects and plans to continue the therapy over the long term, adding that he has felt his confidence return. 

Case #5: 37-Year-Old Male on Topical Finasteride 0.25% + Minoxidil 5%(twice daily) with Weekly Microneedling

This 37-year-old applied a topical finasteride 0.25%/topical minoxidil solution at the dose of 1 ml twice daily, in addition to 1 mm dermastamp/roller weekly, and Nizoral 1% shampoo every other day for scalp care. In the first days of treatment, he described transient systemic sensations including brief testicular ache, mild brain fog, and fatigue, which all resolved promptly without recurrence. 

During weeks 3-8, he began to notice early cosmetic improvement at the crown and part line. By week 12, he showed evident thickening and fill-in compared with baseline, leaving him “very happy” with the 3-month outcome. The user reported high adherence and no side effects beyond the abovementioned early effects. 

Case #6: 46-Year-Old Male on Topical Finasteride 0.1% + Minoxidil 5% (twice daily) with Microneedling

This 46-year-old’s intervention consisted of compounded topical finasteride 0.1% with topical minoxidil 5%, applied twice daily as a solution, with 0.5 ml to the mid-scalp and 0.5 ml to the crown. He additionally began “random” stamping (occasionally daily) at 1.75 mm, which he then standardized to weekly sessions at 0.8–1.0 mm. He likewise supplemented with rosemary oil and biotin. 

He initially suffered a skin reaction and paused the regimen for 4 weeks. After restarting without further issues, he began observing the first notable cosmetic shift at month 2. By month 4, his observed thickening at the crown and improved frontal density. Overall, the Redditor showed apparent improvement across the mid-scalp despite primarily applying the solution to the front and crown. 

Case #7: 32-Year-Old Male on Topical Finasteride 0.025% + Minoxidil 5%

This 32-year-old male’s intervention for the first 12 months was topical finasteride 0.025% monotherapy, which he complemented with minoxidil 5% thereafter. Additionally, he underwent weekly dermastamping, followed a conditioner-only haircare routine, and occasionally applied argan oil. In months 1–3, he notes a rapid normalization of hair shedding. At months 3–12, he reports noticeable temple and frontal regrowth (on finasteride alone), and at months 12–24, he observed maintenance of gains with improved thickness and hair health. He reported consistent adherence and no sexual, cognitive, or systemic side effects.

Case #8: Male (34), 12 Months on Topical Finasteride 0.3% + Minoxidil 6% with Dermastamping; Transitioning to Oral Fin 1.1 mg + Oral Min 3 mg (Daily)

This 34-year-old male’s chosen intervention was a combination of topical finasteride 0.3% and topical minoxidil 6% spray, applied twice daily. Additionally, he underwent microneedling at a depth of 1.5 mm every 10 days. In months 1–2, he observed a shedding phase accompanied by cosmetic worsening. In months 3–4, the shedding slowed, and by month 5, his appearance surpassed baseline. Months 6–11 were marked by steady densification across the hairline, with occasional minor shedding cycles. 

As of the one-year progress report, he was satisfied with the results and transitioned to oral finasteride 1.1 mg + oral minoxidil 3 mg for convenience and to improve adherence. The user noted chest tenderness in his first month on the topical treatment, which resolved after halving his dose. He reported no additional side effects beyond shedding.

Case #9: Male, 4 Months on Topical Finasteride + Topical Minoxidil with Occasional Dermarolling

This male began topical finasteride and minoxidil combination therapy (strength not specified) after noticing the recession. He noted having one dermaroll session to date, in addition to using Nizoral 1% shampoo weekly. He maintained a buzz cut both to optimize topical application to the scalp and to track progress. 

In the 4-month progress report, he noted darkening and thickening of existing fibers, early crown filling, and the emergence of vellus hairs at the hairline. His significant early cosmetic improvement at the 4-month mark is consistent with the response curve for combination finasteride/minoxidil therapy. He reported no side effects to date. 

Case #10: Male (37), 4 Months on Topical Minoxidil+Finasteride Combo (5%/0.1%, 1 ml once daily)

This  37-year-old male’s intervention was a combination of topical finasteride 0.1%/topical minoxidil 5% solution, applied once daily to the crown at a dose of 1 mL. He reported no prior oral use or adjuncts. He also reported a heavy shedding period from weeks 3 to 7. After four months, he noted a visible filling in of the crown and overall improvement compared to both baseline and month 2. He observed a clear recovery after the early shedding phase, expressing satisfaction with the protocol and optimism about maintenance. He reported no adverse effects to date. 

Probable Regrowth Timeline

Based on current clinical data, the expected timeline for regrowth with topical finasteride is gradual and follows a consistent pattern for most users.

Months 0-6: Stabilization

During the first six months, visible improvement is uncommon. While finasteride actively lowers DHT and works to stabilize existing hair follicles, new growth is typically not yet apparent. Some users may notice a reduction in hair shedding, while others could experience a transient increase in hair loss due to the natural turnover of older hairs being replaced by healthier ones. 

Months 6-12: Early Visible Results

Between 6 and 12 months, the first signs of cosmetic enhancement emerge for typical responders. Hair density starts to improve, appears thicker, and the progression of hair loss noticeably slows. For many, this period marks the transition from maintenance to actual visual gains in coverage and texture.

Months 12-24: Peak Gains

The second year of treatment brings the most substantial changes for those who respond well. Increased density and regrowth become much more apparent, with continued accumulation of new growth. Individuals who begin therapy earlier often fare better, while those with advanced hair thinning may experience more stabilization than dramatic regrowth.

Months 24+: Sustaining Progress

Beyond two years, most users maintain the improvements achieved, provided they consistently adhere to the regimen. The initial momentum plateaus, and continued application is essential to preserve gain; stopping treatment typically results in gradual hair loss and a return to baseline within 6-12 months. Some users may pursue combination treatments at this stage to potentially boost further results. 

Overall, topical finasteride requires ongoing commitment and patience, as benefits build gradually and long-term maintenance is needed to sustain outcomes. 

Maximizing Results

To maximize results with topical finasteride, you could choose a multifaceted approach.

Combination Strategies

Pairing topical finasteride with minoxidil has demonstrated clear synergy in multiple clinical trials4,5. Researchers found that the combination significantly boosted both hair density and shaft diameter compared to minoxidil monotherapy, with about 90% of patients exhibiting moderate to marked improvement. Other studies found superior cosmetic outcomes using topical finasteride and minoxidil, strengthening the case for combination therapy6.

Microneedling

While we couldn’t find any direct studies using topical finasteride and microneedling together, it has been shown to be an effective adjunct by increasing the transdermal penetration of topical agents and stimulating growth factors within the scalp. Clinical trials show that microneedling can improve drug delivery and trigger follicular regeneration, making it particularly useful for resistant or slow-to-respond cases11.

Practical Application Tips

For best results with topical finasteride, apply the medication to a clean, thoroughly dried scalp. Use only the recommended dose (usually 1 mL for solutions or the indicated amount for sprays), focusing on areas of active hair loss to avoid excess systemic absorption. 

Monitor your progress with standardized photographs every 3 to 6 months to objectively assess changes. Early reporting of any side effects to your healthcare provider is important, as dosages or formulations can often be adjusted for safety and comfort.

Safety and Side Effects

Topical finasteride has shown a favorable safety profile in clinical trials, with side effects generally mild and less pronounced than those seen with oral formulations^3,12. The most common adverse event is local scalp irritation, such as redness or itching, affecting approximately 3-5% of users. This irritation typically resolves with continued use or minor formulation adjustments.

Sexual side effects, including decreased libido or mild erectile changes, have been reported in about 2-3% of users, with rates significantly lower than those seen with oral finasteride. These effects are usually mild and reversible upon dose reduction or discontinuation of therapy.

Pharmacokinetic studies confirm that topical finasteride results in systemic DHT suppression in the range of 24-48%², compared to 60-70% for the oral form, indicating less overall hormonal impact while retaining efficacy. Importantly, across all major trials of topical finasteride, no severe or life-threatening adverse events have been reported.

Practical Takeaways

• Efficacy of topical finasteride is comparable to oral finasteride in controlled clinical studies, with similar increases in hair count and density.
• The safety profile is favorable due to lower systemic DHT suppression (although some still occurs)
• Visible results typically appear gradually, with most users seeing benefits between 6 and 18 months of consistent treatment. 
• Continuous, consistent use is essential to maintain gains; stopping treatment leads to loss of regrowth over time. 
• Outcomes can be enhanced by combining topical finasteride with minoxidil and/or microneedling, which improves absorbance and regrowth potential.
• Setting realistic goals is important for adherence, satisfaction, and long-term success.

Conclusion

Topical finasteride offers a clinically validated, lower-risk alternative to oral formulations, delivering moderate and sustainable results when used consistently. Its efficacy and safety profile make it ideal for those who value long-term, steady improvement rather than dramatic transformations. Interpreting topical finasteride before-and-after photos with an evidence-based mindset allows users to see possibilities, not guarantees, and reinforces the need for realistic expectations. For people who approach therapy with patience and consistency, topical finasteride stands out as one of today’s most balanced, research-driven solutions for preserving and strengthening existing hair.

References

1. Grymowicz M, Rudnicka E, Podfigurna A, et al. Hormonal Effects on Hair Follicles. Int J Mol Sci. 2020;21(15):5342. doi:10.3390/ijms21155342 
2. Caserini M, Radicioni M, Leuratti C, Terragni E, Iorizzo M, Palmieri R. Effects of a novel finasteride 0.25% topical solution on scalp and serum dihydrotestosterone in healthy men with androgenetic alopecia. CP. 2016;54(01):19-27. doi:10.5414/CP202467 
3. Piraccini BM, Blume‐Peytavi U, Scarci F, et al. Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial. Acad Dermatol Venereol. 2022;36(2):286-294. doi:10.1111/jdv.17738 
4. Suchonwanit P, Iamsumang W, Rojhirunsakool S. Efficacy of Topical Combination of 0.25% Finasteride and 3% Minoxidil Versus 3% Minoxidil Solution in Female Pattern Hair Loss: A Randomized, Double-Blind, Controlled Study. Am J Clin Dermatol. 2019;20(1):147-153. doi:10.1007/s40257-018-0387-0 
5. Suchonwanit P, Srisuwanwattana P, Chalermroj N, Khunkhet S. A randomized, double-blind controlled study of the efficacy and safety of topical solution of 0.25% finasteride admixed with 3% minoxidil vs. 3% minoxidil solution in the treatment of male androgenetic alopecia. J Eur Acad Dermatol Venereol. 2018;32(12):2257-2263. doi:10.1111/jdv.15171 
6. Tanglertsampan C. Efficacy and Safety of 3% Minoxidil versus Combined 3% Minoxidil / 0.1% Finasteride in Male Pattern Hair Loss: A Randomized, Double-Blind, Comparative Study. 2012;95(10). 
7. Hajheydari Z, Akbari J, Saeedi M, Shokoohi L. Comparing the therapeutic effects of finasteride gel and tablet in treatment of the androgenetic alopecia. Indian J Dermatol Venereol Leprol. 2009;75(1):47. doi:10.4103/0378-6323.45220 
8. Mazzarella G, Loconsole G, Cammisa G, Mastrolonardo G, Vena G. Topical finasteride in the treatment of androgenic alopecia. Preliminary evaluations after a 16-month therapy course. Journal of Dermatological Treatment. 1997;8(3):189-192. doi:10.3109/09546639709160517 
9. Chang Y, Zhang W, Zhou J, et al. Clinical efficacy of microneedle combined with 5% Minoxidil solution and finasteride in the treatment of androgenetic alopecia in males. Arch Dermatol Res. 2025;317(1):428. doi:10.1007/s00403-025-03891-y 
10. Wakisaka N, Taira Y ichi, Ishikawa M, et al. Effectiveness of Finasteride on Patients with Male Pattern Baldness Who Have Different Androgen Receptor Gene Polymorphism. J Investig Dermatol Symp Proc. 2005;10(3):293-294. doi:10.1111/j.0022-202X.2005.10123.x 
11. Dhurat R, Sukesh M, Avhad G, Dandale A, Pal A, Pund P. A Randomized Evaluator Blinded Study of Effect of Microneedling in Androgenetic Alopecia: A Pilot Study. Int J Trichology. 2013;5(1):6-11. doi:10.4103/0974-7753.114700 
12. Lee SW, Juhasz M, Mobasher P, Ekelem C, Mesinkovska NA. A Systematic Review of Topical Finasteride in the Treatment of Androgenetic Alopecia in Men and Women. J Drugs Dermatol. 2018;17(4):457-463.